Investigation of in vitro susceptibility and resistance mechanisms to amikacin among diverse carbapenemase-producing Enterobacteriaceae.
Amikacin
/ pharmacology
Carbapenem-Resistant Enterobacteriaceae
/ genetics
Microbial Sensitivity Tests
Anti-Bacterial Agents
/ pharmacology
beta-Lactamases
/ genetics
Bacterial Proteins
/ genetics
Humans
Drug Resistance, Bacterial
/ genetics
Enterobacteriaceae Infections
/ microbiology
Whole Genome Sequencing
Amikacin
Carbapenemase-producing Enterobacteriaceae
Drug resistance
Whole-genome sequencing
Journal
BMC medical genomics
ISSN: 1755-8794
Titre abrégé: BMC Med Genomics
Pays: England
ID NLM: 101319628
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
29
05
2024
accepted:
20
09
2024
medline:
2
10
2024
pubmed:
2
10
2024
entrez:
1
10
2024
Statut:
epublish
Résumé
This study aims to assess the in vitro drug susceptibility of various Carbapenemase-Producing Enterobacteriaceae (CPE) genotypes and elucidate the underlying mechanisms of amikacin resistance. A total of 72 unique CPE strains were collected from the Second Hospital of Jiaxing between 2019 and 2022, including 51 strains of Klebsiella pneumoniae, 11 strains of Escherichia coli, 6 strains of Enterobacter cloacae, 2 strains of Klebsiella aerogenes, 1 strain of Citrobacter freundii, and 1strain of Citrobacter werkmanii. Among these strains, 24 carried bla Out of the 72 CPE strains tested, 41.7% exhibited resistance to amikacin. The drug resistance rates for K. pneumoniae, E. coli, and Enterobacter spp. were 51.0%, 27.3%, and 10.0%, respectively. The majority of the CPE strains (> 90%) displayed resistance to cephalosporins and carbapenems, while most of them were sensitive to polymyxin B and tigecycline (97.2% and 94.4%). The amikacin resistance rate was 100% for strains carrying bla This study identified significant amikacin resistance in CPE strains, particularly in those carrying the bla
Identifiants
pubmed: 39354545
doi: 10.1186/s12920-024-02016-0
pii: 10.1186/s12920-024-02016-0
doi:
Substances chimiques
Amikacin
84319SGC3C
Anti-Bacterial Agents
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
240Subventions
Organisme : the Zhejiang Health Science and Technology Project
ID : 2021KY1109
Organisme : the Zhejiang Health Science and Technology Project
ID : 2021KY1109
Organisme : the Zhejiang Health Science and Technology Project
ID : 2021KY1109
Organisme : the Zhejiang Health Science and Technology Project
ID : 2021KY1109
Organisme : the Zhejiang Health Science and Technology Project
ID : 2021KY1109
Organisme : Science and Technology Bureau of Jiaxing City
ID : 2021AD30104
Organisme : Science and Technology Bureau of Jiaxing City
ID : 2021AD30104
Organisme : Science and Technology Bureau of Jiaxing City
ID : 2021AD30104
Organisme : Science and Technology Bureau of Jiaxing City
ID : 2021AD30104
Organisme : Science and Technology Bureau of Jiaxing City
ID : 2021AD30104
Informations de copyright
© 2024. The Author(s).
Références
Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends in molecular medicine. 2012;18:263–72.
Oli AN, Itumo CJ, Okam PC, Ezebialu IU, Okeke KN, Ifezulike CC, et al. Carbapenem-resistant enterobacteriaceae posing a dilemma in effective healthcare delivery. Antibiotics. 2019;8:156.
doi: 10.3390/antibiotics8040156
pubmed: 31547023
pmcid: 6963482
Arcari G, Carattoli A. Global spread and evolutionary convergence of multidrug-resistant and hypervirulent Klebsiella pneumoniae high-risk clones. Pathogens Global Health. 2023;117:328–41.
doi: 10.1080/20477724.2022.2121362
pubmed: 36089853
Bush K, Bradford PA. Epidemiology of β-Lactamase-producing pathogens. Clin Microbiol Rev. 2020;33:e00047–19.
doi: 10.1128/CMR.00047-19
pubmed: 32102899
pmcid: 7048014
Farhan SM, Raafat M, Abourehab MAS, Abd El-Baky RM, Abdalla S, EL-Gendy AO et al. Effect of Imipenem and Amikacin Combination against Multi-drug Resistant Pseudomonas aeruginosa. Antibiotics. 2021;10.
Atamna-Mawassi H, Huberman-Samuel M, hershcovitz S, Karny-Epstein N, Kola A, Cortés LEL, et al. Interventions to reduce infections caused by multidrug resistant Enterobacteriaceae (MDR-E): a systematic review and meta-analysis. J Infect. 2021;83:156–66.
doi: 10.1016/j.jinf.2021.05.005
pubmed: 34000343
Shakil S, Khan R, Zarrilli R, Khan AU. Aminoglycosides versus bacteria – a description of the action, resistance mechanism, and nosocomial battleground. J Biomed Sci. 2008;15:5–14.
doi: 10.1007/s11373-007-9194-y
pubmed: 17657587
CLSI C. Performance standards for antimicrobial susceptibility testing. Clin Lab Stand Inst. 2016;35:16–38.
Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34:i884–90.
doi: 10.1093/bioinformatics/bty560
pubmed: 30423086
pmcid: 6129281
Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. PLoS Comput Biol. 2017;13:e1005595.
doi: 10.1371/journal.pcbi.1005595
pubmed: 28594827
pmcid: 5481147
Seemann T. Prokka: rapid prokaryotic genome annotation. Bioinformatics. 2014;30:2068–9.
doi: 10.1093/bioinformatics/btu153
pubmed: 24642063
Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2019. gkz935.
Schmartz GP, Hartung A, Hirsch P, Kern F, Fehlmann T, Müller R, et al. PLSDB: advancing a comprehensive database of bacterial plasmids. Nucleic Acids Res. 2022;50:D273–8.
doi: 10.1093/nar/gkab1111
pubmed: 34850116
Robertson J, Nash JH. MOB-suite: software tools for clustering, reconstruction and typing of plasmids from draft assemblies. Microb Genomics. 2018;4.
Starikova EV, Tikhonova PO, Prianichnikov NA, Rands CM, Zdobnov EM, Ilina EN, et al. Phigaro: high-throughput prophage sequence annotation. Bioinformatics. 2020;36:3882–4.
doi: 10.1093/bioinformatics/btaa250
pubmed: 32311023
Puterová J, Martínek T. digIS: towards detecting distant and putative novel insertion sequence elements in prokaryotic genomes. BMC Bioinformatics. 2021;22:258.
doi: 10.1186/s12859-021-04177-6
pubmed: 34016050
pmcid: 8147514
Liu M, Li X, Xie Y, Bi D, Sun J, Li J, et al. ICEberg 2.0: an updated database of bacterial integrative and conjugative elements. Nucleic Acids Res. 2019;47:D660–5.
doi: 10.1093/nar/gky1123
pubmed: 30407568
Bertelli C, Brinkman FS. Improved genomic island predictions with IslandPath-DIMOB. Bioinformatics. 2018;34:2161–7.
doi: 10.1093/bioinformatics/bty095
pubmed: 29905770
pmcid: 6022643
Alikhan N-F, Petty NK, Zakour NLB, Beatson SA. BLAST Ring Image Generator (BRIG): simple prokaryote genome comparisons. BMC Genomics. 2011;12:402.
doi: 10.1186/1471-2164-12-402
pubmed: 21824423
pmcid: 3163573
Lee Y-L, Chen H-M, Hii M, Hsueh P-R. Carbapenemase-producing enterobacterales infections: recent advances in diagnosis and treatment. Int J Antimicrob Agents. 2022;59:106528.
doi: 10.1016/j.ijantimicag.2022.106528
pubmed: 35063651
Chakraborty T, Sadek M, Yao Y, Imirzalioglu C, Stephan R, Poirel L, et al. Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany. J Clin Microbiol. 2021;59:10–1128.
doi: 10.1128/JCM.02238-20
Zhang Y, Chen C, Wu J, Jin J, Xu T, Zhou Y, et al. Sequence-based Genomic Analysis Reveals Transmission of Antibiotic Resistance and virulence among carbapenemase-producing Klebsiella pneumoniae strains. mSphere. 2022;7:e00143–22.
doi: 10.1128/msphere.00143-22
pubmed: 35546482
pmcid: 9241541
Lee C-M, Liao C-H, Lee W-S, Liu Y-C, Mu J-J, Lee M-C, et al. Outbreak of Klebsiella pneumoniae Carbapenemase-2-Producing K. pneumoniae sequence type 11 in Taiwan in 2011. Antimicrob Agents Chemother. 2012;56:5016–22.
doi: 10.1128/AAC.00878-12
pubmed: 22802253
pmcid: 3457369
Han R, Shi Q, Wu S, Yin D, Peng M, Dong D, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) among carbapenem-resistant Enterobacteriaceae isolated from adult and children patients in China. Front Cell Infect Microbiol. 2020;10:314.
doi: 10.3389/fcimb.2020.00314
pubmed: 32719751
pmcid: 7347961
Li X, Zhao D, Li W, Sun J, Zhang X. Enzyme inhibitors: the best strategy to tackle Superbug NDM-1 and its variants. Int J Mol Sci. 2021;23:197.
doi: 10.3390/ijms23010197
pubmed: 35008622
pmcid: 8745225
Sellera FP, Fuentes-Castillo D, Furlan JPR. One health spread of 16S ribosomal RNA methyltransferase-harboring gram-negative bacterial genomes: an overview of the Americas. Pathogens. 2023;12:1164.
doi: 10.3390/pathogens12091164
pubmed: 37764972
pmcid: 10536106
Wu X, Li X, Yu J, Shen M, Fan C, Lu Y et al. Outbreak of OXA-232-producing carbapenem-resistant Klebsiella pneumoniae ST15 in a Chinese teaching hospital: a molecular epidemiological study. Frontiers in Cellular and Infection Microbiology.
Jia H, Zhang Y, Ye J, Xu W, Xu Y, Zeng W, et al. Outbreak of Multidrug-resistant OXA-232-Producing ST15 Klebsiella pneumoniae in a Teaching Hospital in Wenzhou, China. IDR. 2021;14:4395–407.
doi: 10.2147/IDR.S329563
Mancini S, Poirel L, Tritten M-L, Lienhard R, Bassi C, Nordmann P. Emergence of an MDR Klebsiella pneumoniae ST231 producing OXA-232 and RmtF in Switzerland. J Antimicrob Chemother. 2018;73:821–3.
doi: 10.1093/jac/dkx428
pubmed: 29194479
Robertson J, Schonfeld J, Bessonov K, Bastedo P, Nash JHE. A global survey of Salmonella plasmids and their associations with antimicrobial resistance. Microb Genomics. 2023;9.
Baquero F, Martínez JL, Lanza F, Rodríguez-Beltrán V, Galán J, San Millán JC. Evolutionary pathways and trajectories in Antibiotic Resistance. Clin Microbiol Rev. 2021;34:e00050–19.
doi: 10.1128/CMR.00050-19
pubmed: 34190572
pmcid: 8404696
Mathers AJ, Peirano G, Pitout JDD. The role of epidemic resistance plasmids and international high-risk clones in the spread of Multidrug-Resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28:565–91.
doi: 10.1128/CMR.00116-14
pubmed: 25926236
pmcid: 4405625